Lonza Capsugel Celebrates 25 Years of UC-II Undenatured Type II Collagen

Lonza Capsugel is celebrating 25 years since its UC-II undenatured type II collagen hit the market in joint support formulations for humans and companion animals.

“For a quarter of a century, UC-II undenatured type II collagen has set the standard for joint health innovation,” said Randy Flick, director of UC-II and ingredients operations. “In a category often defined by large doses and a range of ingredients, UC-II undenatured type II collagen’s low effective dose differentiates it when compared to hydrolyzed collagen, or glucosamine and chondroitin.”

The ingredient is supported by over 20 studies, including 11 human clinical trials. Its unique mechanism of action supports the body’s natural cartilage repair process and promotes the building of new cartilage, the company reported. In clinical trials, a dose of 40 mg daily was shown to support joint health, flexibility, and mobility in healthy, active adults as young as 20 years old.

The company’s patented manufacturing process and proprietary testing method are central to the ingredient’s quality, Lonza Capsugel noted. The company recently moved production of the ingredient to a facility in Greenwood, South Carolina, to expand manufacturing capacity in response to more global demand.

“The category leadership of UC-II undenatured type II collagne is built on a proven foundation of peer-reviewed research and strategic industry partnerships,” said Frank Romanski, vice president of Lonza Capsugel’s Americas business unit. “Looking ahead, we are committed to advancing joint health science and expanding our pipeline of clinically supported ingredients. Armed with proprietary consumer insights and a litany of scientific evidence, we enable nutraceutical brands to stay one step ahead in this fast-moving market.”